{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:40:24Z","timestamp":1790275224503,"version":"4.1.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past 2 decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents, and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study of patients with MM in 5 Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged \u226518 years diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as \u201cpublic\u201d when primarily funded by federal or local government, and \u201cprivate\u201d when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (n\u00a0=\u00a0339) and private (n\u00a0=\u00a0682) institutions. These 2 groups differed in many respects, with patients from the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6\u00a0months in public institutions and 53.3\u00a0months in private institutions (hazard ratio,\u00a00.84; 95% confidence interval, 0.67-1.04; P\u00a0=\u00a0.109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. This trial was registered at www.clinicaltrials.gov as #NCT03955900.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013838","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T21:15:19Z","timestamp":1733865319000},"page":"1293-1302","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Health care systems as determinants of outcomes in multiple myeloma: final results from the Latin American MYLACRE study"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"first","affiliation":[{"name":"1Cl\u00ednica S\u00e3o Germano, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-4995","authenticated-orcid":false,"given":"Rafael","family":"Gaiolla","sequence":"additional","affiliation":[{"name":"2Medical School of S\u00e3o Paulo State University, Botucatu, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1192-9053","authenticated-orcid":false,"given":"Kenny","family":"Galvez","sequence":"additional","affiliation":[{"name":"3Hospital Pablo Tobon Uribe, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6320-8867","authenticated-orcid":false,"given":"Guillermina","family":"Remaggi","sequence":"additional","affiliation":[{"name":"4Fundaleu, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1167-7186","authenticated-orcid":false,"given":"Natalia","family":"Schutz","sequence":"additional","affiliation":[{"name":"5Hospital Italiano de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosane","family":"Bittencourt","sequence":"additional","affiliation":[{"name":"6Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0140-9548","authenticated-orcid":false,"given":"Angelo","family":"Maiolino","sequence":"additional","affiliation":[{"name":"7Instituto Am\u00e9ricas de Ensino, Pesquisa e Inova\u00e7\u00e3o, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-6911","authenticated-orcid":false,"given":"Guillermo","family":"Quintero-Vega","sequence":"additional","affiliation":[{"name":"8Fundaci\u00f3n Santa Fe de Bogota, Bogota, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Silvana","family":"Cugliari","sequence":"additional","affiliation":[{"name":"9Instituto de Oncolog\u00eda Angel H. Roffo, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Moises Tobias","family":"Braga","sequence":"additional","affiliation":[{"name":"10Hospital S\u00e3o Paulo, Federal University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1668-8132","authenticated-orcid":false,"given":"Carolina Colaco","family":"Villarim","sequence":"additional","affiliation":[{"name":"11Liga Contra o C\u00e2ncer, Natal, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-4731","authenticated-orcid":false,"given":"Edvan","family":"Crusoe","sequence":"additional","affiliation":[{"name":"12lnstituto D'or Oncologia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia Ines","family":"Enrico","sequence":"additional","affiliation":[{"name":"13Hospital Italiano La Plata, La Plata, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"Caiero","sequence":"additional","affiliation":[{"name":"14Hospital Privado Centro Medico de Cordoba SA, C\u00f3rdoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jandey","family":"Bigonha","sequence":"additional","affiliation":[{"name":"15Hospital do Servidor P\u00fablico Estadual, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Lemos","family":"Moura","sequence":"additional","affiliation":[{"name":"16A.C. Camargo Cancer Center, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9406-0879","authenticated-orcid":false,"given":"Jair","family":"Figueroa","sequence":"additional","affiliation":[{"name":"17Hospital Universit\u00e1rio Mayor, Mederi, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9876-222X","authenticated-orcid":false,"given":"Claudia Lucia","family":"Sossa Melo","sequence":"additional","affiliation":[{"name":"18Fundaci\u00f3n Oftalmol\u00f3gica de Santander, Cl\u00ednica FOSCAL, Floridablanca, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0982-7074","authenticated-orcid":false,"given":"Milton","family":"Lombana","sequence":"additional","affiliation":[{"name":"19Clinica de Occidente, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Pei","sequence":"additional","affiliation":[{"name":"20Janssen Research & Development, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1742-1448","authenticated-orcid":false,"given":"Mariana","family":"Fernandez","sequence":"additional","affiliation":[{"name":"21Janssen-Cilag, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline","family":"Saes","sequence":"additional","affiliation":[{"name":"22Janssen-Cilag Ltda, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7322-7482","authenticated-orcid":false,"given":"Damila Cristina","family":"Trufelli","sequence":"additional","affiliation":[{"name":"22Janssen-Cilag Ltda, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"1","key":"2025032512170346400_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2025032512170346400_bib2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","article-title":"The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers","volume":"157","author":"Dyba","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10272","key":"2025032512170346400_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"2025032512170346400_bib4","unstructured":"World Health Organization\n          . Cancer fact sheets. Accessed 4 May 2024. https:\/\/gco.iarc.fr\/today\/en\/fact-sheets-cancers."},{"key":"2025032512170346400_bib5","unstructured":"World Health Organization\n          . Multiple Myeloma. Accessed 4 May 2024. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/35-multiple-myeloma-fact-sheet.pdf."},{"issue":"1","key":"2025032512170346400_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"issue":"5","key":"2025032512170346400_bib7","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers"},{"issue":"9513","key":"2025032512170346400_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"9594","key":"2025032512170346400_bib9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"19","key":"2025032512170346400_bib10","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2025032512170346400_bib11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2025032512170346400_bib12","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025032512170346400_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2025032512170346400_bib14","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025032512170346400_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2025032512170346400_bib16","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025032512170346400_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025032512170346400_bib18","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3324\/haematol.11637","article-title":"Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma","volume":"93","author":"Hungria","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"2025032512170346400_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00277-016-2866-9","article-title":"Observational study of multiple myeloma in Latin America","volume":"96","author":"Hungria","year":"2017","journal-title":"Ann Hematol"},{"key":"2025032512170346400_bib20","first-page":"1","article-title":"Epidemiology of hematologic malignancies in real-world settings: findings from the hemato-oncology Latin America observational registry study","volume":"5","author":"Tietsche de Moraes Hungria","year":"2019","journal-title":"J\u00a0Glob Oncol"},{"issue":"6","key":"2025032512170346400_bib21","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/j.clml.2021.12.009","article-title":"Real-world evidence of epidemiology and clinical outcomes in multiple myeloma, findings from the registry of hemato-oncologic malignancies in Colombia, observational study","volume":"22","author":"Abello","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2025032512170346400_bib22","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00277-020-03983-x","article-title":"Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Multiple)","volume":"99","author":"Riva","year":"2020","journal-title":"Ann Hematol"},{"issue":"13","key":"2025032512170346400_bib23","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1080\/10428194.2020.1804558","article-title":"Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study","volume":"61","author":"Pena","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025032512170346400_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1590\/1516-3180.2015.0223030416","article-title":"Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study","volume":"134","author":"Kerbauy","year":"2016","journal-title":"Sao Paulo Med J"},{"issue":"12","key":"2025032512170346400_bib25","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025032512170346400_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","article-title":"Median follow-up in clinical trials","volume":"9","author":"Shuster","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025032512170346400_bib27","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"4","key":"2025032512170346400_bib28","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00277-019-03602-4","article-title":"Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries","volume":"98","author":"Hungria","year":"2019","journal-title":"Ann Hematol"},{"issue":"1","key":"2025032512170346400_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cam4.2656","article-title":"Connect MM Registry as a national reference for United States multiple myeloma patients","volume":"9","author":"Ailawadhi","year":"2020","journal-title":"Cancer Med"},{"issue":"2","key":"2025032512170346400_bib30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/10428194.2022.2140283","article-title":"Real-world assessment of the treatment patterns and outcomes among patients with multiple myeloma across different risk stratification criteria in the United States: a retrospective cohort study","volume":"64","author":"Rahman","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025032512170346400_bib31","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bjh.16139","article-title":"Development of a prognostic model for overall survival in multiple myeloma using the Connect((R)) MM patient registry","volume":"187","author":"Terebelo","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2025032512170346400_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/ejh.13976","article-title":"Survival outcomes for patients with multiple myeloma in France: a retrospective cohort study using the Systeme National des Donnees de Sante national healthcare database","volume":"111","author":"Leleu","year":"2023","journal-title":"Eur J Haematol"},{"issue":"30","key":"2025032512170346400_bib33","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2217\/fon-2023-0120","article-title":"Real-world evidence of multiple myeloma treated from 2013 to 2019 in the hospital district of Helsinki and Uusimaa, Finland","volume":"19","author":"Vikkula","year":"2023","journal-title":"Future Oncol"},{"issue":"6","key":"2025032512170346400_bib34","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10192","key":"2025032512170346400_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"2025032512170346400_bib36","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/j.clml.2020.11.013","article-title":"Multiple myeloma in hispanics: incidence, characteristics, survival, results of discovery, and validation using real-world and connect MM registry data","volume":"21","author":"Kaur","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2025032512170346400_bib37","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1080\/10428194.2022.2092852","article-title":"Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada","volume":"63","author":"Jimenez-Zepeda","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"2025032512170346400_bib38","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1002\/cam4.4137","article-title":"Front-line treatment patterns in multiple myeloma: an analysis of U.S.-based electronic health records from 2011 to 2019","volume":"10","author":"Kumar","year":"2021","journal-title":"Cancer Med"},{"key":"2025032512170346400_bib39","doi-asserted-by":"crossref","first-page":"113921","DOI":"10.1016\/j.ejca.2024.113921","article-title":"Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: an analysis using linked Nordic registries","volume":"201","author":"Abildgaard","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"2025032512170346400_bib40","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.clml.2018.08.005","article-title":"Analysis of availability and access of anti-myeloma drugs and impact on the management of multiple myeloma in Latin American countries","volume":"19","author":"Pessoa de Magalhaes Filho","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2025032512170346400_bib41","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clml.2018.04.007","article-title":"Heterogeneity of second-line treatment for patients with multiple myeloma in the connect MM registry (2010-2016)","volume":"18","author":"Jagannath","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"2025032512170346400_bib42","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/cancers15225338","article-title":"Evolution of pharmacological treatments and associated costs for multiple myeloma in the public healthcare system of Catalonia: a retrospective observational study","volume":"15","author":"Garrido-Alejos","year":"2023","journal-title":"Cancers"},{"key":"2025032512170346400_bib43","doi-asserted-by":"crossref","first-page":"106542","DOI":"10.1016\/j.leukres.2021.106542","article-title":"Association of insurance disparities and survival in adults with multiple myeloma: a non-concurrent cohort study","volume":"104","author":"Makhani","year":"2021","journal-title":"Leuk Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/6\/1293\/2359050\/blooda_adv-2024-013838-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/6\/1293\/2359050\/blooda_adv-2024-013838-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T12:25:23Z","timestamp":1742905523000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/6\/1293\/534448\/Health-care-systems-as-determinants-of-outcomes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,3,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013838","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}